Department of Laboratory Hematology and Medical Oncology, University Health Network, Toronto, Ontario, Canada.
Leuk Lymphoma. 2012 Feb;53(2):202-7. doi: 10.3109/10428194.2011.608449. Epub 2011 Sep 19.
Cytogenetic testing is now routinely performed for the prognostic work-up of multiple myeloma (MM). The abnormalities del(17p), t(4;14) and del(13q) have been established as predictors of poor outcome in patients with MM treated with conventional chemotherapy or stem cell transplant; chromosome 1q gains and 1p losses have also been identified as novel prognostic factors. In recent years, bortezomib and lenalidomide have emerged as effective treatments for both relapsed/refractory and newly diagnosed MM. However, the effect of cytogenetic abnormalities is unclear among patients with MM treated with these novel agents. Here we review recent studies that analyze the impact of specific genomic aberrations on the outcome of MM treated with bortezomib and/or lenalidomide.
细胞遗传学检测现已常规用于多发性骨髓瘤（MM）的预后评估。del(17p)、t(4;14)和 del(13q)等异常已被确定为接受常规化疗或干细胞移植治疗的 MM 患者不良预后的预测因子；染色体 1q 增益和 1p 缺失也被确定为新的预后因素。近年来，硼替佐米和来那度胺已成为复发/难治性和新诊断 MM 的有效治疗药物。然而，这些新型药物治疗的 MM 患者的细胞遗传学异常的影响尚不清楚。在这里，我们回顾了最近的研究，这些研究分析了特定基因组异常对硼替佐米和/或来那度胺治疗的 MM 患者结局的影响。
